8-azaguanine is an anti-metabolic drug activated by HPRT1. Increasing the gene dose of HPRT1 in hyperploid breast cancer can control the sensitivity of this drug, which may be related to the function of HPRT1 in purine biosynthesis (19). The gene discussed is HPRT1; the disease is breast carcinoma.